Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Buffettology -- Ignore unavailable to you. Want to Upgrade?

To: James Clarke who wrote (2534)	6/16/2000 7:35:00 AM
From: valueminded	Read Replies (1) \| Respond to of 4690

James: In reference to the REL deal, I see the risk reward scenario as favorable and bought in yesterday. Given the background of Luk, I give a relatively high probability for this going through. My understanding is that dd should be done by about mid July, based on 30days after all materials supplied. In terms of the debt loading, the sale to travelors should help some in that area as that occurs prior to the LUK buyout. (agree/disagree) On a different note, it appears that EBSC management is bent on destroying the value of the company. Their salvo against the proxy seemed to be a little antagonistic for mgmt which has done little to enhance shareholder value. These types of battles never end very well for the shareholder as management usually rapes the company before they are relieved of command. Have your thoughts changed ? As a value play, have you looked at PRXL ? They have a business in assisting biotechs thru the regulatory process, lots of cash, and good cash flow. My only negative is the insider selling. As a decent spec (Mike Burry may be able shed light on this) is CURE. They are subject to medicaid investigation (never a good thing, but surface analysis seems that they may be guilt by association). They have some insider buying, decent cash flow and lots of cash. They operate wound care centers. thanks